Fate Therapeutics to Present at Upcoming May Investor Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company focused on cellular immunotherapies, announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference will be held on May 12, 2022, at 12:20 PM ET in Las Vegas, Nevada. Additionally, the H.C. Wainwright Annual Global Life Sciences Conference will be available on demand starting May 24, 2022, at 7:00 AM ET. Interested investors can access live webcasts of the presentations on the company’s website. Fate Therapeutics aims to develop innovative cell therapies for cancer treatment.
- None.
- None.
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
- BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 12:20 PM ET in Las Vegas, Nevada
- H.C. Wainwright Annual Global Life Sciences Conference available on demand on Tuesday, May 24, 2022 at 7:00 AM ET
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
FAQ
What investor conferences will Fate Therapeutics present at in May 2022?
What is the schedule for Fate Therapeutics at the BofA Securities Conference?
When can I access the presentations from Fate Therapeutics' conferences?
What focus areas does Fate Therapeutics have in its immuno-oncology pipeline?
Where is Fate Therapeutics headquartered?
